SCHEMBL3394497

SCHEMBL3394497

Cc1cc(C(=O)n2cnc3c(Br)nc(N)nc32)nc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
ADORA2A P29274 8/20 0.39
ADORA1 P30542 8/20 0.39
BACE1 P56817 1/20 0.39
KDM4E B2RXH2 2/20 0.37
GRM2 Q14416 4/20 0.37
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP1A2 P05177 1/20 0.36
NUDT1 P36639 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RECQL P46063 1/20 0.36
RAB9A P51151 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2B P29275 1/20 0.36
POLB P06746 1/20 0.35
ALOX12 P18054 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3391520 0.74 HSP90AA1 (0.47) ALDH1A1ADORA2AADORA1BACE1CYP1A2
SCHEMBL3392715 0.71 HSP90AB1 (0.41) ADORA2AADORA1
SCHEMBL1395393 0.70 HSP90AB1 (0.46) ADORA2AADORA1
SCHEMBL4798283 0.70 ADORA2A (0.39) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL3396436 0.68 HSP90AA1 (0.47)
SCHEMBL27941539 0.67 GRM2 (0.69) ALDH1A1BACE1GRM2CYP1A2
SCHEMBL2377166 0.67 ALDH1A1 (0.73) ALDH1A1BACE1KDM4EGRM2HPGD
SCHEMBL3395542 0.64 HSP90AA1 (0.55)
SCHEMBL28234814 0.63 ALDH1A1 (1.00) ALDH1A1BACE1KDM4EGRM2HPGD
SCHEMBL2467305 0.62 ALDH1A1 (0.65) ALDH1A1BACE1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 ALDH1A1 827/4885ADORA2A 1896/4885ADORA1 3394/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 ALDH1A1 827/4885ADORA2A 1896/4885ADORA1 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.